version 1.3.1093 and 2021.09.0 build 351 (RStudio)
90
Structured Review
RStudio
version 1.3.1093 and 2021.09.0 build 351
Version 1.3.1093 And 2021.09.0 Build 351, supplied by RStudio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+1%2E3%2E1093+and+2021%2E09%2E0+build+351/version+1+3+1093+and+2021+09+0+build+351/pm39876087-106-50-56
Average 90 stars, based on 1 article reviews
Version 1.3.1093 And 2021.09.0 Build 351, supplied by RStudio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/version+1%2E3%2E1093+and+2021%2E09%2E0+build+351/version+1+3+1093+and+2021+09+0+build+351/pm39876087-106-50-56
Average 90 stars, based on 1 article reviews
version 1.3.1093 and 2021.09.0 build 351 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Integrated Longitudinal Population Dose-Hemoglobin Response of Daprodustat Following Dose Titration in Patients With Anemia in Chronic Kidney Disease. Article Snippet: Daprodustat, a novel oral hypoxiainducible factor prolyl hydroxylase inhibitor is approved in the United States for the treatment of anemia due to chronic kidney disease (CKD) in adults receiving dialysis for at least 4 months.. Pharmacodynamic dosehemoglobin (DoseHgb) models were developed as daprodustat progressed through development.. To support global phase III development, a dosetitration algorithm, guided by simulations from the initial DoseHgb model based on phase II clinical data, was implemented. |